Rosiglitazone abolishes MAP kinases activities in the liver of db/db.
TXM-CB3 abolishes ERK1/2 and p38MAPK activities in the liver of db/db mice.
TXM-CB3, TXM-CB13 (DY70) and TXM-CB16 (DY71) reverse oxidative stress in FAO cells.
TXM-CB3 rescues insulin-induced Akt/PKB activation from oxidative stress.
TXM-peptides could prevent insulin resistance lowering inflammatory consequences.